12. Segments

3 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Three Months Ended June 30,
	2017			2016
Revenues:
Aethlon	$	–		$	4,635
ESI		–			–
Total Revenues	$	392,073		$	4,635
Operating Losses:
Aethlon	$	(1,141,406	)	$	(1,092,990	)
ESI		(18,843	)		(38,662	)
Total Operating Loss	$	(1,160,249	)	$	(1,131,652	)
Net Losses:
Aethlon	$	(1,826,708	)	$	(2,097,887	)
ESI		(18,843	)		(38,662	)
Net Loss Before Non-Controlling Interests	$	(1,845,551	)	$	(2,136,549	)
Cash:
Aethlon	$	326,464		$	1,291,537
ESI		742			2,722
Total Cash	$	327,206		$	1,294,259
Total Assets:
Aethlon	$	492,324		$	1,419,226
ESI		16,827			41,806
Total Assets	$	509,151		$	1,461,032
Capital Expenditures:
Aethlon	$	23,705		$	1,545
ESI		–			–
Capital Expenditures	$	23,705		$	1,545
Depreciation and Amortization:
Aethlon	$	9,326		$	5,323
ESI		–			4,895
Total Depreciation and Amortization	$	9,326		$	10,218
Interest Expense:
Aethlon	$	(188,604	)	$	(42,167	)
ESI		–			–
Total Interest Expense	$	(188,604	)	$	(42,167	)